To further evaluate the effect of potential clinical confounders on CD61+ and CD45+ EVs, we performed a multivariate regression analysis, taking into account the concentrations of CD61+ and CD45+ EVs above the median as a dependent variable and (i) age, (ii) gender (female), (iii) PAH severity (WHO class), and (iv) therapy with prostacyclin analogues as independent variables. The gene discussed is PTPRC; the disease is pulmonary arterial hypertension.